ArticleTheranostics2018
Hypoxia-triggered single molecule probe for high-contrast NIR II/PA tumor imaging and robust photothermal therapy.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 234 citations in OpenAlex.
- Molecular fluorophores for in vivo bioimaging in the second near-infrared window.European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Activatable NIR-II photoacoustic probes for cancer imaging and imaging-guided therapy.Bioactive materials · 2026Review
- Hypoxia-Activated NIR-II Fluorescent Probes for Breast Tumor Imaging viaChemical & biomedical imaging · 2026Article
- Activatable smart contrast agents for photoacoustic imaging.Smart molecules : open access · 2026Review
- Delineating precise surgical resection areas: recent advances in NIR-II fluorescence imaging molecular probes.Frontiers in oncology · 2026Review
- Real-Time Detection of Reduced Nitroreductase with a Reversible Fluorescent Probe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Multifunctional Liposomes: Smart Nanomaterials for Enhanced Photodynamic Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- An activatable unimolecular phototheranostic agent for synergistic chemo-photodynamic therapy.Chemical science · 2025Article
- Near-infrared II nanomaterials for hypoxic TME diagnosis and therapy.Nanomedicine (London, England) · 2025Review
- Advancing Cancer Treatment: Innovative Materials in PDT and Diagnostic Integration.International journal of nanomedicine · 2025Review
- Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies.ACS omega · 2024Review
- Totally Caged Type I Pro-Photosensitizer for Oxygen-Independent Synergistic Phototherapy of Hypoxic Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Article
- Recent Advances in the Application of Nitro(het)aromatic Compounds for Treating and/or Fluorescent Imaging of Tumor Hypoxia.Molecules (Basel, Switzerland) · 2024Review
- Evaluations of an Early Change in Tumor Pathophysiology in Response to Radiotherapy with Oxygen Enhanced Electron Paramagnetic Resonance Imaging (OE EPRI).Molecular imaging and biology · 2024Article
- Ultra-photostable small-molecule dyes facilitate near-infrared biophotonics.Nature communications · 2024Article
- Real-time fluorescent monitoring of phase I xenobiotic-metabolizing enzymes.RSC advances · 2024Review
- Theranostic Fluorescent Probes.Chemical reviews · 2024Review
- Lactoferrin docking NIR-II cyanine dye as a potentiated phototheranostic for synchronous multimodal bioimaging and tumor photo-immunotherapy.Theranostics · 2024Article
- Recent advances and applications of nitroreductase activable agents for tumor theranostic.Frontiers in pharmacology · 2024Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia is a common characteristic of solid tumors. This important feature is associated with resistance to radio-chemotherapy, which results in poor prognosis and probability of tumor recurrence. Taking advantage of background-free NIR II fluorescence imaging and deeper-penetrating photoacoustic (PA) imaging, we developed a hypoxia-triggered and nitroreductase (NTR) enzyme-responsive single molecule probe for high-contrast NIR II/PA tumor imaging and hypoxia-activated photothermal therapy (PTT), which will overcome cellular resistance during hypoxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.